There were no serious adverse events related to competition in a study of 129 young athletes with implantable cardioverter defibrillators (ICDs), providing reassurance that moderate-to-intense physical activity in this population may be safer than previously thought.

Individuals with clinical depression could face a more than seven-fold increased risk of atrial fibrillation (AF), especially in the earliest stages of their diagnosis, a population study out of Denmark suggests.

People who are frail and older than 65 are at a 50 percent increased risk of major bleeding during hospitalizations for heart attack compared to nonfrail patients, according to research published Nov. 19 in JACC: Cardiovascular Interventions.

The use of intravascular ultrasound (IVUS) to guide PCI leads to further improvements in event-free survival between one and two years post-procedure, according to a report from the ADAPT-DES study published in Circulation: Cardiovascular Interventions.

The risk of major stroke was higher in the 30 days following surgical aortic valve replacement (SAVR) compared to transfemoral TAVR, according to a propensity-matched analysis from the PARTNER trials published Nov. 12 in the Journal of the American College of Cardiology.

An observational study of nearly 35,000 Scandinavian patients with type 2 diabetes (T2D) has found sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of prescription drugs approved by the FDA to lower blood sugar in adults with T2D, may almost double patients’ risks of lower limb amputation and diabetic ketoacidosis compared to glucagon-like peptide 1 (GLP1) receptor agonists.

Heart patients with symptoms of peripheral artery disease (PAD) continue to see low rates of prescriptions for antiplatelets, statins and ACE inhibitors, despite those drugs’ potential to prevent against major events like stroke, according to research published Nov. 15 in Stroke.

A machine learning-based risk calculator developed to assess an individual’s long-term risk for atherosclerotic cardiovascular disease (ASCVD) identified 13 percent more high-risk patients and recommended unnecessary statin therapy 25 percent less often than standard risk assessment tools in initial tests, researchers reported in the Journal of the American Heart Association.